These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19067367)

  • 61. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.
    Letendre S; Marquie-Beck J; Capparelli E; Best B; Clifford D; Collier AC; Gelman BB; McArthur JC; McCutchan JA; Morgello S; Simpson D; Grant I; Ellis RJ;
    Arch Neurol; 2008 Jan; 65(1):65-70. PubMed ID: 18195140
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group.
    Curran A; Monteiro P; Domingo P; Villar J; Imaz A; Martínez E; Fernández I; Knobel H; Podzamczer D; Iribarren JA; Peñaranda M; Crespo M;
    J Antimicrob Chemother; 2014 May; 69(5):1390-6. PubMed ID: 24415645
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapy.
    Chaparro J; Reeds DN; Wen W; Xueping E; Klein S; Semenkovich CF; Bae KT; Quirk EK; Powderly WG; Yarasheski KE; Li E
    Metabolism; 2005 May; 54(5):561-7. PubMed ID: 15877283
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Polymorphism of protease genes in patients infected with HIV-1 and response to therapy including a protease inhibitor].
    Mouroux M; Bossi P; Yvon-Groussin A; Delaugerre C; Valantin MA; Tubiana R; Coutellier A; Bonmarchand M; Bricaire F; Katlama C; Agut H; Huraux JM; Calvez V
    Pathol Biol (Paris); 1999 May; 47(5):549-52. PubMed ID: 10418038
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study.
    Mocroft A; Phillips AN; Friis-Møller N; Colebunders R; Johnson AM; Hirschel B; Saint-Marc T; Staub T; Clotet B; Lundgren JD;
    Antivir Ther; 2002 Mar; 7(1):21-30. PubMed ID: 12008784
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen.
    Barrail-Tran A; Morand-Joubert L; Poizat G; Raguin G; Le Tiec C; Clavel F; Dam E; Chêne G; Girard PM; Taburet AM;
    Antimicrob Agents Chemother; 2008 May; 52(5):1642-6. PubMed ID: 18285478
    [TBL] [Abstract][Full Text] [Related]  

  • 68. P-glycoprotein in blood CD4 cells of HIV-1-infected patients treated with protease inhibitors.
    Bossi P; Legrand O; Faussat AM; Legrand M; Bricaire F; Marie JP; Agut H; Diquet B; Katlama C; Huraux JM; Calvez V
    HIV Med; 2003 Jan; 4(1):67-71. PubMed ID: 12534962
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml.
    Imaz A; Llibre JM; Navarro J; Curto J; Clotet B; Crespo M; Ferrer E; Saumoy M; Tiraboschi JM; Murillo O; Podzamczer D
    Antivir Ther; 2014; 19(6):569-77. PubMed ID: 24458091
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options.
    Naggie S; Hicks C
    J Antimicrob Chemother; 2010 Jun; 65(6):1094-9. PubMed ID: 20418273
    [TBL] [Abstract][Full Text] [Related]  

  • 71. ABC of AIDS. Antiretroviral drugs.
    Weller IV; Williams IG
    BMJ; 2001 Jun; 322(7299):1410-2. PubMed ID: 11397751
    [No Abstract]   [Full Text] [Related]  

  • 72. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.
    de la Rosa R; Ruíz-Mateos E; Rubio A; Abad MA; Vallejo A; Rivero L; Genebat M; Sánchez-Quijano A; Lissen E; Leal M
    J Antimicrob Chemother; 2004 Jan; 53(1):95-101. PubMed ID: 14657091
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patients.
    Hellinger J; Cohen C; Morris A; Sheble-Hall S; Gordon D; Foy C; Jackson-Pope L; Shevitz A; van Schaic E
    HIV Clin Trials; 2005; 6(2):107-17. PubMed ID: 15983895
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
    Ortega KL; Vale DA; Magalhães MH
    J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patients.
    Kozal MJ; Hullsiek KH; Leduc R; Novak RM; MacArthur RD; Lawrence J; Baxter JD;
    Antivir Ther; 2006; 11(4):457-63. PubMed ID: 16856619
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor.
    Rakotoambinina B; Médioni J; Rabian C; Jubault V; Jais JP; Viard JP
    J Acquir Immune Defic Syndr; 2001 Aug; 27(5):443-9. PubMed ID: 11511820
    [TBL] [Abstract][Full Text] [Related]  

  • 77. HIV-1 protease inhibitors. A review for clinicians.
    Deeks SG; Smith M; Holodniy M; Kahn JO
    JAMA; 1997 Jan; 277(2):145-53. PubMed ID: 8990341
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Impact of intensification with raltegravir on HIV-1-infected individuals receiving monotherapy with boosted PIs.
    Puertas MC; Gómez-Mora E; Santos JR; Moltó J; Urrea V; Morón-López S; Hernández-Rodríguez A; Marfil S; Martínez-Bonet M; Matas L; Muñoz-Fernández MA; Clotet B; Blanco J; Martinez-Picado J
    J Antimicrob Chemother; 2018 Jul; 73(7):1940-1948. PubMed ID: 29635527
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The relationship between race and HIV-distal sensory polyneuropathy in a large cohort of US women.
    Anziska Y; Helzner EP; Crystal H; Glesby MJ; Plankey M; Weber K; Golub E; Burian P
    J Neurol Sci; 2012 Apr; 315(1-2):129-32. PubMed ID: 22123155
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-naïve women of childbearing age.
    Möller J; Desai K; Simpson K; Baran RW; Van de Steen O; Dietz B; Gooch K
    J Med Econ; 2014 Apr; 17(4):250-8. PubMed ID: 24351091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.